STOCK TITAN

Lifecore Biomedical Inc - LFCR STOCK NEWS

Welcome to our dedicated news page for Lifecore Biomedical (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lifecore Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lifecore Biomedical's position in the market.

Rhea-AI Summary
Lifecore Biomedical, Inc. (LFCR) announced Ernst & Young LLP's decision not to stand for reappointment as the Company's independent registered public accounting firm for the fiscal year ending May 26, 2024. The board of directors has started a search for a replacement. Lifecore also plans to provide a business update on April 1, 2024, including financial data for fiscal year 2024 and commercial business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. appoints Paul Josephs as the new CEO, concludes strategic review, and announces operational updates. The Board of Directors decides to continue with the standalone strategic plan after evaluating various alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.32%
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) filed its Annual Report on Form 10-K for FY23 with the SEC, restating financial statements for FY22 and FY21. The restatements corrected errors in capitalized interest, inventory valuation, and other adjustments. Notable adjustments include write-downs of inventories, recording reserves for excess and obsolete inventories, and adjustments to revenues and cost of sales. The Company also provided supplemental financial data for its Lifecore business to aid investors in analyzing restated financials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.32%
Tags
earnings
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) faces potential delisting from Nasdaq due to non-compliance with filing financial reports. The company received a Staff Delisting Determination but has the opportunity to appeal and seek a stay of any delisting action. Lifecore Biomedical is working to complete the restatement of its financial statements and file the overdue reports to regain compliance with Nasdaq's Listing Rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. (LFCR) received a notice from Nasdaq stating that it is not in compliance with listing rules due to delayed filings of financial reports. The company has been granted an exception period until February 12, 2024, to regain compliance. Lifecore Biomedical is working diligently to complete the filings and intends to file them as promptly as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) has finalized updated commercial arrangements with long-term customer Alcon, including an 8-year extension of its contract manufacturing agreement, an amendment to its Hyaluronic Acid supply agreement, and a new Storage Services Agreement. The company also received a limited waiver and amendment to its credit agreements with Alcon and BMO, providing additional financial flexibility. Lifecore continues to work on becoming current on its periodic reports, including completing the filing of its Annual Report on Form 10-K for the fiscal year ended May 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) provided a business update, indicating progress towards completing its Annual Report on Form 10-K for the fiscal year ended May 28, 2023. The Company is actively working on its development portfolio, with 32 projects in development and a pipeline across pre-clinical through late-phase of development. Lifecore is also evaluating potential strategic alternatives, with no set timetable for completion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced that the U.S. Department of Justice has declined to prosecute the company for violations of the Foreign Corrupt Practices Act involving its former subsidiary, Yucatan Foods L.P. The company has agreed to pay disgorgement of $406,505 and continue cooperating with ongoing investigations and potential future prosecutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. receives notice of non-compliance with Nasdaq listing rule
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
Rhea-AI Summary
SHL Medical enters co-marketing partnership with Lifecore Biomedical
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
partnership
Lifecore Biomedical Inc

Nasdaq:LFCR

LFCR Rankings

LFCR Stock Data

162.20M
17.93M
4.53%
74.76%
5.75%
Plastics Material and Resin Manufacturing
Manufacturing
Link
US
Santa Clara

About LFCR

landec corporation (nasdaq:lndc) is a leading innovator of diversified health and wellness solutions within the packaged food and biomaterial markets. apio, landec's food business, is the leader in branded, packaged fresh vegetables in north america, utilizing its proprietary breatheway® packaging technology to naturally extend the shelf life of fresh produce. apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the eat smart® brand to consumers through club and retail grocery stores. lifecore biomedical, landec's biomaterial business, is a fully integrated contract development and manufacturing organization (cdmo) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for fda regulated medical devices and drugs to customers for applications in a wide array of markets including ophthalmic, orthopedic and oncology. for more information abo